Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2, Open-Label Safety and Efficacy Evaluation of CRS-207 in Combination With Epacadostat in Adults With Platinum-Resistant Ovarian, Fallopian, or Peritoneal Cancer

NCT02575807 is registered in ClinicalTrials.gov with Aduro Biotech, Inc. as lead sponsor.

NCT NCT02575807
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02575807 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2, Open-Label Safety and Efficacy Evaluation of CRS-207 in Combination With Epacadostat in Adults With Platinum-Resistant Ovarian, Fallopian, or Peritoneal Cancer
Lead sponsor
Aduro Biotech, Inc.
Phase
Phase 1/2
Overall status
Terminated
Start date
March 8, 2016
Completion date
May 8, 2018
Enrollment
35 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

platinum-resistant fallopian cancer, platinum-resistant ovarian cancer, platinum-resistant peritoneal cancer